CHLA-01-MED Xenograft Model Service for Medulloblastoma

The CHLA-01-MED xenograft model offers a clinically relevant preclinical platform for evaluating therapeutic candidates against medulloblastoma, the most common malignant pediatric brain tumor. Alfa Cytology leverages this well-characterized Group 4 medulloblastoma cell line to deliver robust, translational xenograft studies tailored to your drug discovery and development pipeline.

Overview of CHLA-01-MED Xenograft Model for Medulloblastoma

Medulloblastoma is an embryonal tumor of the cerebellum that accounts for approximately 20% of all pediatric central nervous system malignancies. Molecular profiling has classified medulloblastoma into four principal subgroups---WNT, SHH, Group 3, and Group 4---each with distinct genomic drivers, clinical behaviors, and therapeutic vulnerabilities. The CHLA-01-MED cell line, originally established from an 8-year-old male patient with CNS-disseminated medulloblastoma, is classified within the Group 4 subgroup. This classification is significant because Group 4 medulloblastomas represent the largest patient cohort, frequently exhibit metastatic dissemination at diagnosis, and remain the subgroup with the least well-defined targeted therapeutic strategies, making robust preclinical models essential for advancing drug development.

In xenograft applications, CHLA-01-MED cells are typically propagated as suspension neurospheres in serum-free DMEM/F12 medium supplemented with B-27, EGF, and bFGF, preserving their stem-like characteristics and genomic fidelity. When introduced into immunocompromised murine hosts, these cells reliably form tumors that recapitulate key histopathological and molecular features of human Group 4 medulloblastoma, including small round blue cell morphology, high mitotic index, and expression of neural stem cell markers. The model has been extensively utilized in published literature to evaluate chemotherapeutic agents, targeted inhibitors, radiation response, and metastatic mechanisms, establishing it as a cornerstone for preclinical medulloblastoma research.

• Efficacy Testing: Evaluating the in vivo anti-tumor activity of novel compounds, small molecules, biologics, or combination therapies targeting Group 4 medulloblastoma.
• Mechanistic Studies: Investigating the complex molecular pathways driving medulloblastoma progression and metastatic dissemination, and how treatments intersect with these pathways.
• Biomarker Discovery: Identifying and validating potential biomarkers for treatment response or resistance in a controlled in vivo environment.

Figure 1. BMI1(High);CHD7(Low) signature renders MB cells more responsive to MAPK inhibition. (Badodi, Sara, et al., 2022)

Cell Line Information: CHLA-01-MED

The CHLA-01-MED cell line is a well-established human medulloblastoma line with comprehensive molecular characterization. Its classification within the Group 4 subgroup and retention of stem-like characteristics in neurosphere culture makes it unique among available medulloblastoma cell lines and essential for preclinical research targeting the largest and least-defined patient cohort.

Our Services

Alfa Cytology provides end-to-end CHLA-01-MED xenograft model services, from cell line authentication and quality-controlled expansion to orthotopic or subcutaneous implantation, in-life tumor monitoring, and comprehensive endpoint analysis. Our preclinical oncology team ensures that every study is designed with rigorous scientific rationale, delivering reproducible data to accelerate your medulloblastoma therapeutic development programs.

Workflow of CHLA-01-MED Xenograft Model Construction

Alfa Cytology follows a standardized, quality-controlled workflow to construct CHLA-01-MED xenograft models, ensuring reproducible tumor growth and reliable pharmacological readouts. At Alfa Cytology, we adhere to an optimized, multi-step workflow to ensure maximum take rates and reproducible growth kinetics. The streamlined workflow involves:

1. Cell Line Authentication and Expansion: CHLA-01-MED cells are retrieved from authenticated cryopreserved stocks and expanded under defined serum-free neurosphere conditions. Short tandem repeat (STR) profiling and mycoplasma testing are performed to confirm identity and sterility prior to inoculation.
2. Recipient Mouse Preparation: Immunocompromised recipient mice (typically athymic nude or NOD scid gamma strains) are acclimatized under pathogen-free conditions. Animal health status is verified, and cohorts are randomized based on body weight and baseline health assessments.
3. Cell Harvest and Preparation: Exponentially growing CHLA-01-MED neurospheres are harvested, gently dissociated into cell suspensions or small clusters, and resuspended in a serum-free medium/Matrigel mixture at the optimal concentration for tumorigenicity.
4. Tumor Cell Inoculation: For subcutaneous models, cells are implanted into the flank under sterile surgical conditions. For orthotopic cerebellar models, stereotactic injection into the mouse cerebellum is performed using precision coordinates to recapitulate anatomical tumor localization.
5. In-Life Monitoring and Tumor Tracking: Mice are monitored daily for general health, body weight, and neurological signs. Tumor dimensions are measured by caliper (subcutaneous) or advanced imaging modalities such as MRI or bioluminescence (orthotopic) at defined intervals to establish growth kinetics.
6. Study Intervention and Endpoint Analysis: Upon reaching predetermined tumor volume or study duration, mice are euthanized humanely. Tumors are excised, weighed, and processed for downstream analyses including histopathology (H&E, IHC), molecular profiling, pharmacokinetic assessment, and biomarker quantification.

Figure 2: Schematic workflow illustrating the derivation and construction of the CHLA-01-MED Xenograft Model at Alfa Cytology.

Case Study-CHLA-01-MED Xenograft Model Development

Alfa Cytology has successfully established and validated CHLA-01-MED xenograft models for multiple preclinical drug development programs targeting pediatric medulloblastoma. Our internal datasets demonstrate consistent tumor take rates, predictable growth kinetics, and responsive pharmacodynamic endpoints across subcutaneous and orthotopic implantation settings. Detailed growth curves, survival analyses, and histopathological validation data are available upon request under confidentiality agreements. Please contact our scientific team to discuss specific case data relevant to your therapeutic program.

Why Choose Alfa Cytology?

Partnering with Alfa Cytology for your CHLA-01-MED medulloblastoma xenograft studies provides distinct advantages in preclinical execution and data quality.

• Verified Cell Line Integrity: Rigorous cell line authentication and mycoplasma screening ensure experimental integrity from study initiation.
• High Take Rates and Consistency: Flexible model configurations including subcutaneous, orthotopic cerebellar, and bioluminescent reporter-enabled designs.
• Comprehensive Analytical Support: Comprehensive in-life monitoring with advanced imaging capabilities for real-time tumor tracking and quantitative endpoint analysis.
• Tailored Study Designs: Dedicated preclinical oncology team with deep expertise in pediatric CNS tumor models and regulatory-compliant study documentation.
• Standardized Protocols: Streamlined project timelines with transparent communication and customized reporting to support IND-enabling and publication objectives.

Contact Us

Ready to advance your medulloblastoma therapeutic program with a validated CHLA-01-MED xenograft model? Reach out to Alfa Cytology today to discuss your study requirements, review available data packages, and design a customized preclinical strategy that meets your development milestones. Please reach out to us today via our inquiry form or email to learn more about our CHLA-01-MED Xenograft Model services.

For research use only. Not intended for any clinical use.